A Delphi consensus on the use of a low-dose multicomponent medication for the prevention and early add-on treatment of influenza-like illness

Background: Influenza and Influenza-Like Illness (ILI), collectively referred to as "Flu Syndrome" (FS) in this consensus, represent a major global health burden. Their high incidence, with an estimated 1 billion annual cases globally and 3–5 million severe cases, coupled with relatively limited prophylactic and therapeutic options beyond vaccination, underscores a significant challenge in clinical practice.Objectives: This study aimed to establish a formal expert consensus on the definition, management, and potential role of a low-dose multicomponent medication (Omeogriphi®) as a broad-spectrum strategy for the prevention and early add-on treatment of FS.Methods: A modified Delphi consensus process was employed. A scientific committee formulated 15 statements across two domains: 1) the definition and epidemiology of FS, and 2) its management, focusing on Omeogriphi®. A panel of 112 Italian primary care and private practice physicians with experience in using Omeogriphi® rated their agreement on a 5-point Likert scale. Consensus was predefined as ≥66.6% agreement.Results: A high level of consensus was achieved on all 15 statements (79%–99% agreement). The panel reached strong agreement on the clinical definition, epidemiological impact, and complication risks of FS. Furthermore, there was robust consensus that Omeogriphi® is considered a viable option for both prophylaxis and early treatment of FS, with a favorable safety profile.Conclusions: This Delphi consensus provides expert-driven, clinically relevant insights into the management of FS and the potential role of a low-dose multicomponent medication. The findings consolidate current clinical experience and establish a foundation for designing future rigorous clinical trials to evaluate the efficacy of this approach objectively.